Advertisement

HBV and HCV infection in i.v. drug addicts; coinfection with HIV

  • P. Botti
  • A. Pistelli
  • F. Gambassi
  • A. M. Zorn
  • L. Caramelli
  • S. Peruzzi
  • C. Smorlesi
  • E. Masini
  • P. F. Mannaioni
Part of the Archives of Virology book series (ARCHIVES SUPPL, volume 4)

Summary

A group of 122 drug addict patients were studied to evaluate the incidence of HIV, HBV, HCV infections and of laboratory findings of hepatic damage. Our data show that hepatic damage is more frequent in patients affected by HBV-HCV coinfection than those with HBV or HCV infection alone and that HIV positivity supports HBV-HCV coinfection.

Keywords

Hepatic Damage Drug Addict NANB Hepatitis Standard Blood Test Toxicological Unit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kuo G, Choo QL, Alter HJ et al (1989) An assay for circulating antibodies to a major etiologic virus of human NANB hepatitis. Science 244: 362–364PubMedCrossRefGoogle Scholar
  2. 2.
    Mattson L, Weiland O, Glaumann H (1989) Chronic non-A, non-B hepatitis developed after transfusion, illicit self injection or sporadically. Outcoming during long term follow-up. Liver 9: 120–127Google Scholar
  3. 3.
    Esteban JI, Esteban R, Viladomiu L et al (1989) Hepatitis C virus antibodies among risk groups in Spain. Lancet ii, 8658: 294–297CrossRefGoogle Scholar
  4. 4.
    Martin P, Di Bisceglie AM, Kassianides C et al (1989) Rapidly progressive non-A, non-B hepatitis in patients with HIV infection. Gastroenterology 97: 1559–1561PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • P. Botti
    • 1
  • A. Pistelli
    • 1
  • F. Gambassi
    • 1
  • A. M. Zorn
    • 1
  • L. Caramelli
    • 1
  • S. Peruzzi
    • 1
  • C. Smorlesi
    • 1
  • E. Masini
    • 1
  • P. F. Mannaioni
    • 1
  1. 1.Department of Preclinical and Clinical PharmacologyFlorence UniversityFlorenceItaly

Personalised recommendations